BrandWikiReturn

Mydecine

Mydecine Innovations Group, or simply Mydecine, is an American and Canadian pharmaceutical company that is developing psychedelics and entactogens as medicines.[2]

In August 2022, it was reported that Mydecine was experiencing financial difficulties and might cease operations.[2][3] However, the company was able to obtain more funding and did not shutdown.[2] Mydecine made the first legal import of magic mushrooms into Canada in 2021.[4][5]

Mydecine's drug candidates include the psychedelics psilocybin (MYCO-001, MYCO-003),[6][7][8] MYCO-004 (a patch-delivered tryptamine),[9][10] and MYCO-005 (a novel aza psilocin analogue with putatively better safety)[11][12][13] and the novel MDMA-like entactogens MYCO-002 (putatively safer),[14][15] MYCO-006 (short-acting),[16][17][3][18] and MYCO-007 (short-acting).[19][20][21][1]

Although the chemical structures of most of its drug candidates have not been disclosed, Mydecine has patented 5-BZT-MDMA (MY100) and 6-BZT-MDMA (MY101) as short-acting MDMA analogues.[22][23][24]

See also

External links

References

  1. Gary Simonelli. The Use of AI Technology is Increasing the Potential of Mydecine Innovations Group to Successfully Commercialize Psychedelic Drug Candidates CEOCFO, 10 April 2023, retrieved 29 January 2025^
  2. Mydecine Looks Set to Shutter; MindMed Gains 'Meme Stock' Status; atai 'Streamlilnes' Pipeline; California Decrim. Bill Gutted Psychedelic Alpha, 19 August 2022, retrieved 29 January 2025^
  3. Debra Borchardt. Psilocybin Company Mydecine Is Down To $300k In Cash Green Market Report, 17 August 2022, retrieved 29 January 2025^
  4. Jared Gnam. Mydecine to make first legal import of psilocybin mushrooms into Canada Mugglehead Investment Magazine, 11 December 2020, retrieved 29 January 2025^
  5. Laura Elizabeth Lansdowne. Behind the World-First Export of Jamaican Psilocybin Mushrooms Neuroscience from Technology Networks, 19 February 2021, retrieved 29 January 2025^
  6. Psilocybin - Mydecine Innovations Group - AdisInsight adisinsight.springer.com^
  7. Delving into the Latest Updates on MYCO-001 with Synapse Synapse, 23 January 2025, retrieved 29 January 2025^
  8. Delving into the Latest Updates on MYCO-003 with Synapse Synapse, 23 January 2025, retrieved 29 January 2025^
  9. MYCO 004 - AdisInsight adisinsight.springer.com^
  10. Delving into the Latest Updates on MYCO-004 with Synapse synapse.patsnap.com^
  11. Research programme: second generation psilocin analogs - Mydecine Innovations Group - AdisInsight adisinsight.springer.com^
  12. Delving into the Latest Updates on MYCO-005 with Synapse Synapse, 1 November 2024, retrieved 1 November 2024^
  13. The Influence of Stakeholder Interests on Safety Outcome Reporting in Psychedelic Research and Implications for Science Communication Trends Psychiatry Psychother, August 2024^
  14. MYCO 002 - AdisInsight adisinsight.springer.com^
  15. Delving into the Latest Updates on MYCO-002 with Synapse synapse.patsnap.com^
  16. Research programme: short acting methylenedioxymethamphetamine analogs - Mydecine Innovations Group - AdisInsight adisinsight.springer.com^
  17. Delving into the Latest Updates on MYCO-006 with Synapse synapse.patsnap.com^
  18. Rowan Dunne. Mydecine's MDMA with rapid onset and a short duration shows promising results Mugglehead Investment Magazine, 24 April 2023, retrieved 29 January 2025^
  19. Delving into the Latest Updates on MYCO-007 with Synapse synapse.patsnap.com^
  20. 2309151616480990.pdf retrieved 23 October 2024^
  21. Mydecine Innovations Group. Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs GlobeNewswire News Room, 19 July 2022, retrieved 23 October 2024^
  22. Mydecine. Novel short-acting psychoactive compounds of the mdma class Google Patents, 5 January 2024, retrieved 23 October 2024^
  23. 1-(1,3-benzoxathiol-5-yl)-N-methylpropan-2-amine PubChem, retrieved 23 October 2024^
  24. 1-(1,3-benzoxathiol-5-yl)-N,N-dimethylpropan-2-amine PubChem, retrieved 23 October 2024^